Efficacy of Anti-Interleukin-2 Receptor Antibody (Daclizumab) in Reducing the Incidence of Acute Rejection After Renal Transplantation
Author:
Publisher
Briefland
Subject
Urology
Reference17 articles.
1. LRISK FACTORS FOR CHRONIC REJECTION IN RENAL ALLOGRAFT RECIPIENTS
2. THE IMPACT OF ACUTE REJECTION EPISODES ON LONG-TERM GRAFT FUNCTION AND OUTCOME IN 1347 PRIMARY RENAL TRANSPLANTS TREATED BY 3 CYCLOSPORINE REGIMENS
3. Improved Graft Survival after Renal Transplantation in the United States, 1988 to 1996
4. Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Peptides, Antibodies, Peptide Antibodies and More;International Journal of Molecular Sciences;2019-12-13
2. Novel surgical techniques, regenerative medicine, tissue engineering and innovative immunosuppression in kidney transplantation;Archives of Medical Science;2016
3. Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates;Expert Review of Clinical Immunology;2014-12-15
4. Efficacy of plasmapheresis on donor-specific antibody reduction by HLA specificity in post-kidney transplant recipients;Transfusion;2014-11-11
5. Therapeutic uses of anti- 4-integrin (anti-VLA-4) antibodies in multiple sclerosis;International Immunology;2014-10-17
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3